Exelixis, Inc. — Form 10-K Summary
Period: Fiscal year ended December 28, 2012 (52 weeks; figures are presented on a calendar-year basis in the filing). The request identifies “2011 Q4,” but the supplied filing is the 2012 annual report, not a 2011 quarterly filing.
Business context
Exelixis is a biotechnology company focused on cancer therapies. It concentrated its proprietary development and commercialization resources on cabozantinib, marketed as COMETRIQ. The FDA approved COMETRIQ on November 29, 2012, for progressive, metastatic medullary thyroid cancer (MTC); the U.S. commercial launch followed in January 2013, after the reporting period. No COMETRIQ product revenue was recorded in 2012. Other pipeline programs were principally licensed to collaborators.
Financial results and liquidity
| Metric | 2012 | 2011 |
|---|---|---|
| Revenue | $47.5 million | $289.6 million |
| Operating expenses | $169.9 million | $200.1 million |
| Operating income (loss) | $(122.4) million | $89.5 million |
| Net income (loss) | $(147.6) million | $75.7 million |
| Net income (loss) per diluted share | $(0.92) | $0.58 |
| Cash and investments | $634.0 million | $283.7 million |
| Working capital | $350.8 million | $136.5 million |
| Debt carrying amount | $335.7 million | $181.5 million |
- Revenue fell 84%, primarily because 2011 included accelerated recognition of collaboration license revenue upon termination of agreements with Bristol-Myers Squibb and Sanofi. Those accelerations included $99.1 million and $53.1 million, respectively; 2011 also included a $15.3 million Sanofi termination payment.
- 2012 revenue was entirely collaboration-related: Bristol-Myers Squibb represented 66%, Merck 22%, and Daiichi Sankyo 12%. The filing reports no product sales in 2012.
- Research and development expense declined 18% to $128.9 million; general and administrative expense declined 4% to $31.8 million. Restructuring charges were $9.2 million.
- Operating cash use was approximately $123.1 million; investing activities used $259.5 million and financing activities provided $478.4 million. Financing included $203.5 million net from stock offerings and $277.7 million net from the 2019 convertible notes.
- Cash and investments included restricted balances and $87.0 million of investments maintained as collateral for the Silicon Valley Bank facility. Cash and cash equivalents alone were $170.1 million.
- Debt includes $287.5 million principal of 4.25% convertible notes due 2019, $124.0 million initial principal of secured Deerfield notes due 2015, and Silicon Valley Bank borrowings. The 2019 notes had a $149.8 million year-end carrying amount after accounting for the conversion feature and debt discount. The filing cites $496.8 million of total consolidated indebtedness through maturity, excluding trade payables.
- 2012 net margin was approximately negative 311% (calculated from reported net loss and revenue); operating margin was approximately negative 258%.
Material changes and business developments
- COMETRIQ’s pivotal EXAM trial showed median progression-free survival of 11.2 months versus 4.0 months on placebo (hazard ratio 0.28; p<0.0001); partial responses were 27% versus 0%. Overall survival was not statistically different at the planned interim analysis.
- Research and development spending continued to shift toward cabozantinib. Restructurings from 2010–2012 reduced headcount by 422 employees; cumulative restructuring charges were $52.1 million.
- In August 2012, Exelixis raised capital through common-stock and convertible-note offerings. Shares outstanding increased to approximately 183.7 million at year-end, from 135.6 million a year earlier.
- Genentech initiated a phase 3 trial of GDC-0973 (XL518) with vemurafenib in November 2012. Exelixis retains U.S. profit-sharing and ex-U.S. royalty rights, subject to the agreement, and a time-limited U.S. co-promotion option.
Outlook, commentary, and risks
- Management expected available cash, investments, and anticipated collaborator funding to support operations for at least 12 months after year-end 2012. It also warned that future capital needs would be substantial and that additional financing might be needed.
- Management planned to initiate phase 3 cabozantinib trials in hepatocellular cancer and renal cell cancer in 2013, and expected top-line results from the two ongoing phase 3 prostate cancer trials in 2014. These are forward-looking plans, not assured outcomes.
- The COMET-1 trial has an overall-survival endpoint; COMET-2 has a pain-palliation endpoint. The FDA had raised design concerns about COMET-2, and Exelixis proceeded without a Special Protocol Assessment.
- COMETRIQ carries boxed warnings for gastrointestinal perforations and fistulas, and severe hemorrhage. The label also describes other serious risks and precautions, including thrombotic events, hypertension, wound complications, and embryo-fetal toxicity.
- Key risks include clinical-trial failure or delay, uncertain product uptake and reimbursement, competition, reliance on third-party manufacturers and distribution providers, dependence on collaborators for revenue, and debt-service and covenant obligations. Management anticipated continued net losses and negative operating cash flow.
- Contractual cash obligations totaled $585.5 million at year-end, including debt, leases, and purchase obligations. The Silicon Valley Bank facility requires collateral balances tied to outstanding borrowings; covenant failure could trigger acceleration. Exelixis reported no material off-balance-sheet arrangements.
- A former officer filed a lawsuit in December 2012 seeking unspecified damages; the matter was at an early stage and the company said it could not estimate any potential loss. The filing otherwise states that Exelixis was not party to material legal proceedings.
- The independent auditor issued an unqualified opinion on the financial statements and internal control over financial reporting; management reported effective disclosure controls and no material weaknesses.
Important facts for investors to verify
- Whether COMETRIQ launch uptake, net pricing, reimbursement, and sales in the small MTC market support management’s commercial expectations.
- Current status, enrollment, safety findings, and results timing for COMET-1 and COMET-2, and the planned liver- and kidney-cancer trials; also verify the FDA’s current position on trial designs and any regulatory requirements.
- Cash available for operations after restricted and collateral balances, cash burn, financing needs, and compliance with bank and note covenants and scheduled Deerfield prepayments.
- Whether collaborator programs achieve milestones or generate royalties, given the concentration of 2012 revenue among three partners and the non-risk-adjusted nature of the disclosed potential milestone pool.
- Manufacturing and supply continuity, postmarketing study obligations, the former-officer litigation, and any material changes to the risk factors or outlook since the filing.